Monitoring late-onset toxicities in phase I trials using predicted risks.

@article{Bekele2008MonitoringLT,
  title={Monitoring late-onset toxicities in phase I trials using predicted risks.},
  author={Benjamin Nebiyou Bekele and Yuan Ji and Y X Shen and Peter F. Thall},
  journal={Biostatistics},
  year={2008},
  volume={9 3},
  pages={
          442-57
        }
}
Late-onset (LO) toxicities are a serious concern in many phase I trials. Since most dose-limiting toxicities occur soon after therapy begins, most dose-finding methods use a binary indicator of toxicity occurring within a short initial time period. If an agent causes LO toxicities, however, an undesirably large number of patients may be treated at toxic doses before any toxicities are observed. A method addressing this problem is the time-to-event continual reassessment method (TITE-CRM, Cheung… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

BAYESIAN PHASE I DOSE FINDING IN CANCER TRIALS

VIEW 7 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Dose-finding designs for Phase II clinical trials

VIEW 13 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.

  • Journal of the Royal Statistical Society. Series C, Applied statistics
  • 2019
VIEW 1 EXCERPT
CITES METHODS